Boehringer Ingelheim International GmbH
Boehringer Ingelheim International GmbH, a leading global pharmaceutical company, is headquartered in Ingelheim am Rhein, Germany. Founded in 1885, the company has established a strong presence in the healthcare industry, focusing on human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. With a commitment to innovation, Boehringer Ingelheim is renowned for its core products, including prescription medications for respiratory diseases, cardiovascular conditions, and diabetes management. The company’s unique approach to research and development has positioned it as a key player in the market, consistently delivering groundbreaking therapies. Notable achievements include significant advancements in veterinary medicine and a robust pipeline of new treatments, reinforcing its status as one of the top pharmaceutical firms globally. Boehringer Ingelheim continues to prioritise improving patient outcomes and animal health through its dedicated efforts in scientific excellence.
DitchCarbon Score
How does Boehringer Ingelheim International GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boehringer Ingelheim International GmbH's score of 10 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Boehringer Ingelheim International GmbH's reported carbon emissions
Boehringer Ingelheim International GmbH, headquartered in Germany (DE), currently does not provide specific carbon emissions data or reduction targets. Without available figures on their emissions, it is unclear how their operations impact climate change. However, the company is likely engaged in various sustainability initiatives typical of the pharmaceutical industry, focusing on reducing their carbon footprint and enhancing environmental responsibility. As the industry increasingly prioritises climate commitments, Boehringer Ingelheim may be aligning with broader trends towards sustainability, although specific details on their commitments or targets are not disclosed.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boehringer Ingelheim International GmbH is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
